Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMARTO ONE for Neurodegenerative Diseases
NCT05947409Unknown
- Start
- Aug 2023
- Primary completion
- Jun 2024
01
Overview
Open-label trial in neurodegenerative disease, cognitive impairment, sleep disorder and 2 more. Primary endpoints: Montreal Cognitive Assessment at 4 weeks, Pittsburgh Sleep Quality Index at 4 weeks and 1 more. Status: unknown.
02
Conditions
neurodegenerative diseasecognitive impairmentsleep disorderanxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05947409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947409.